PIL challenges Centre’s HPV vaccination drive, seeks Supreme Court intervention over consent, safety and accountability
'No fake Abhayrab vaccine exported': Indian Immunologicals clarifies after Delhi Police seize counterfeit rabies vaccine batch- Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal
- Growing peptide trend raises safety concerns among doctors
- 4.439.719.2617.87
- 4.499.669.2317.82
- 4.429.709.3017.81
- RPG Life Sciences to deploy Rs 500 crore in next 12 months to bolster manufacturing, API capabilities
- Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets
- Seized Abhayrab vials not manufactured by company: Indian Immunologicals Limited
- Govt flags Abhayrab rabies vaccine batch as substandard, probes if spurious, document shows
- Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepiness
- Moopen family picks up additional stake in Aster DM Quality Care for Rs 350 cr
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
- Drug cos refuse to take sole responsibility for overpricing
- Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio
- Max Healthcare to invest Rs 6,200 cr to reach 10,000-bed capacity in 3 years: CMD
- RPG Life Sciences subsidiary acquires Raghava Life Sciences' API biz for Rs 135 cr
Top Mutual Funds
3 M(%)
6 M(%)
1 YR(%)
3 YRS(%)
MORE NEWS
Biotech
Govt eases loan licence requirement for 'outsourced' sterilisation of medical gear- Danish firm Novonesis to roll out ₹3,000 crore Maharashtra investment over 2-3 years
- Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical
- Lord’s Mark Industries announces license for biomescan analytics platform
- Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovation
Healthcare
Growing peptide trend raises safety concerns among doctors- RPG Life Sciences to deploy Rs 500 crore in next 12 months to bolster manufacturing, API capabilities
- Seized Abhayrab vials not manufactured by company: Indian Immunologicals Limited
- Moopen family picks up additional stake in Aster DM Quality Care for Rs 350 cr
- Max Healthcare to invest Rs 6,200 cr to reach 10,000-bed capacity in 3 years: CMD
Pharmaceuticals
- PIL challenges Centre’s HPV vaccination drive, seeks Supreme Court intervention over consent, safety and accountability
- 'No fake Abhayrab vaccine exported': Indian Immunologicals clarifies after Delhi Police seize counterfeit rabies vaccine batch
- Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal
- Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets
- Govt flags Abhayrab rabies vaccine batch as substandard, probes if spurious, document shows